A new working paper by Harvard economist Rebecca Diamond suggests that women who lose weight using GLP-1 medications like Ozempic or Wegovy experience significant improvements in employment and relationship outcomes. The study, which has not been peer-reviewed, analyzed data comparing GLP-1 users, non-users, and individuals interested in using the drugs but had not yet started. Both groups had high body mass indexes (BMIs).
Key Findings
- Employment: Non-working women on GLP-1s were 27 percentage points more likely to secure a job within 18 months of weight loss compared to those who wanted but did not use the drugs.
- Relationships: Women on GLP-1s were 29 percentage points more likely to start living with a partner or get married over the same period.
The study controlled for variables like health and race but cautioned against interpreting the results as definitive proof of weight discrimination. Diamond noted that the findings align with broader research indicating that obesity carries social and economic penalties, particularly for women.
Limitations and Context
- No Impact on Existing Jobs: The study found no evidence that GLP-1 use helped women already employed earn more or work additional hours.
- Relationship Stability: Women already in relationships showed no significant changes in relationship status based on GLP-1 use.
- First Impressions Matter: The findings suggest that initial perceptions—such as those in job interviews or social settings—play a crucial role in these outcomes.
Diamond emphasized that the paper is a working draft and requires further peer review. The study highlights the broader societal biases against obesity but does not establish causality between GLP-1 use and improved outcomes.